The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Open accessAbstract
PURPOSE: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. METHODS: Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m 2 once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m 2 once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m 2 over 3 hours day 1, IP cisplatin 75 mg/m 2 day 2, and IP paclitaxel 60 mg/m 2 day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22. RESULTS: A total of 1,560 participants were enrolled and had 84.8 months of follow-up. The median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual disease of 1 cm or less, median PFS was 26.9 (IV-carboplatin), 28.7 (IP-carboplatin), and 27.8 months (IP cisplatin), respectively. Median PFS for patients with stage II/III and no residual disease was 35.9, 38.8, and 35.5 months, respectively. Median overall survival for all enrolled was 75.5, 78.9, and 72.9 months, respectively, and median overall survival for stage II/III with no gross residual disease was 98.8 months, 104.8 months, and not reached. Mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores (Gynecologic Oncology Group) were similar for all arms, but the mean Trial Outcome Index of the Functional Assessment of Cancer Therapy–Ovary scores during chemotherapy were statistically worse in the IP cisplatin arm. CONCLUSION: Compared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Yost, K. J., & Eton, D. T. (2005) · Evaluation & the Health Professions · doi:10.1177/0163278705275340 · Cited by 382
Reliability and validity of the functional assessment of cancer therapy-ovarian
Basen-Engquist, K., Bodurka-Bevers, D., Fitzgerald, M. A., Webster, K., Cella, D., Hu, S., & Gershenson, D. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1809 · Cited by 280
Cited by
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Treatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Cristea, M., DeRosa, M., Eisenhauer, E. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0007 · Cited by 715
Self-citationCancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Tewari, K. S., Burger, R. A., Enserro, D., Norquist, B. M., Swisher, E. M., Brady, M. F., Bookman, M. A., Fleming, G. F., Huang, H., Homesley, H. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01009 · Cited by 483
Self-citation
Metadata
- Authors
- Walker, J. L., Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., DiSilvestro, P. A., Fujiwara, K., Alberts, D. S., Zheng, W., Tewari, K. S., Cohn, D. E., Powell, M. A., Van Le, L., Davidson, S. A., Gray, H. J., Rose, P. G., Aghajanian, C., Myers, T., Alvarez Secord, A., Rubin, S. C., & Mannel, R. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-06-01
- Volume
- 37
- Issue
- 16
- Pages
- 1380-1390
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2937594202
- Cited by
- 231
- References
- 5
- FWCI
- 29.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. https://app.cochat.ai/papers/10.1200/jco.18.01568
- The paper
- Walker, J. L., Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., DiSilvestro, P. A., Fujiwara, K., Alberts, D. S., Zheng, W., Tewari, K. S., Cohn, D. E., Powell, M. A., Van Le, L., Davidson, S. A., Gray, H. J., Rose, P. G., Aghajanian, C., Myers, T., Alvarez Secord, A., . . . Mannel, R. S. (2019). Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.01568
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.